![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
Feature|Videos|March 27, 2024
Bioanalytical Methods to Optimize Drug Development: Hybrid LC-MS vs LBA
Drs Dawn Dufield and Dominic Warrino, KCAS Bioanalytical and Biomarker Services, share expertise on using Hybrid LC-MS versus LBA for bioanalytical analysis.
Selecting the right bioanalytical method to support qualitative and quantitative analysis requires flexibility and expertise from a CRO equipped to adapt to industry advancements.
Learn more:
- Understand when to use LC-MS, LBA or both.
- Learn why keeping LBA and Hybrid LC-MS in the forefront of your studies can result in big benefits.
- Understand the best method to optimize your drug development outcomes.
See the entire 45-minute deep-dive broken into an 11-part video series,
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)


